Jeffrey Bennett
Concepts (552)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 85 | 2025 | 132 | 18.560 |
Why?
| | Aquaporin 4 | 57 | 2025 | 95 | 8.900 |
Why?
| | Multiple Sclerosis | 34 | 2025 | 457 | 5.930 |
Why?
| | Autoantibodies | 51 | 2025 | 1452 | 5.120 |
Why?
| | Immunoglobulin G | 52 | 2024 | 892 | 4.430 |
Why?
| | Optic Neuritis | 15 | 2023 | 41 | 4.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 20 | 2025 | 798 | 2.690 |
Why?
| | B-Lymphocytes | 16 | 2024 | 845 | 2.280 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 17 | 2024 | 51 | 1.740 |
Why?
| | Optic Nerve | 12 | 2023 | 65 | 1.630 |
Why?
| | Immunologic Factors | 6 | 2025 | 236 | 1.560 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 39 | 1.530 |
Why?
| | Remyelination | 2 | 2025 | 15 | 1.510 |
Why?
| | Astrocytes | 15 | 2025 | 210 | 1.470 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 28 | 1.370 |
Why?
| | Neuroglia | 5 | 2024 | 171 | 1.030 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 85 | 1.010 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 217 | 1.000 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1412 | 1.000 |
Why?
| | Complement C5 | 1 | 2025 | 80 | 0.930 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 62 | 0.930 |
Why?
| | Magnetic Resonance Imaging | 15 | 2025 | 3574 | 0.920 |
Why?
| | Humans | 147 | 2025 | 136965 | 0.900 |
Why?
| | Macaca mulatta | 8 | 2024 | 182 | 0.880 |
Why?
| | Epitopes | 8 | 2025 | 476 | 0.880 |
Why?
| | Cerebellum | 4 | 2025 | 214 | 0.860 |
Why?
| | Retinal Degeneration | 2 | 2023 | 38 | 0.850 |
Why?
| | Brain | 12 | 2024 | 2711 | 0.840 |
Why?
| | Complement System Proteins | 7 | 2019 | 321 | 0.820 |
Why?
| | Natalizumab | 4 | 2020 | 40 | 0.820 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 68 | 0.800 |
Why?
| | Methylprednisolone | 1 | 2023 | 63 | 0.800 |
Why?
| | Animals | 65 | 2025 | 36882 | 0.790 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 30 | 0.770 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 861 | 0.750 |
Why?
| | Disease Models, Animal | 16 | 2025 | 4276 | 0.740 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 137 | 0.730 |
Why?
| | Autoimmunity | 4 | 2017 | 897 | 0.720 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 83 | 0.720 |
Why?
| | Myelin Sheath | 7 | 2025 | 167 | 0.700 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 40 | 0.670 |
Why?
| | Immunotherapy | 4 | 2020 | 627 | 0.660 |
Why?
| | Complement C1q | 1 | 2019 | 37 | 0.610 |
Why?
| | Plasma Cells | 7 | 2017 | 72 | 0.610 |
Why?
| | Complement Activation | 4 | 2022 | 407 | 0.610 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 20 | 0.610 |
Why?
| | Glial Fibrillary Acidic Protein | 5 | 2024 | 99 | 0.600 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 28 | 0.590 |
Why?
| | Inflammation | 11 | 2023 | 2831 | 0.590 |
Why?
| | Cell Membrane | 3 | 2017 | 710 | 0.590 |
Why?
| | Aminopyridines | 1 | 2019 | 97 | 0.580 |
Why?
| | Papilledema | 4 | 2023 | 39 | 0.580 |
Why?
| | Central Nervous System | 5 | 2023 | 262 | 0.580 |
Why?
| | Adult | 44 | 2025 | 37715 | 0.580 |
Why?
| | Mice | 32 | 2025 | 17705 | 0.570 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 76 | 0.570 |
Why?
| | Double-Blind Method | 10 | 2025 | 1904 | 0.560 |
Why?
| | Pyrroles | 1 | 2019 | 212 | 0.560 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 329 | 0.560 |
Why?
| | Organic Chemicals | 1 | 2019 | 125 | 0.560 |
Why?
| | Glucocorticoids | 2 | 2019 | 519 | 0.550 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 50 | 0.540 |
Why?
| | Middle Aged | 41 | 2025 | 33226 | 0.540 |
Why?
| | Microglia | 2 | 2019 | 249 | 0.540 |
Why?
| | Disease Management | 2 | 2018 | 615 | 0.530 |
Why?
| | CHO Cells | 8 | 2019 | 165 | 0.530 |
Why?
| | Female | 64 | 2025 | 73002 | 0.530 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.520 |
Why?
| | Biomarkers | 13 | 2025 | 4095 | 0.520 |
Why?
| | Spinal Cord | 8 | 2023 | 371 | 0.510 |
Why?
| | Antigens, CD19 | 5 | 2022 | 123 | 0.510 |
Why?
| | Retina | 5 | 2023 | 296 | 0.510 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 144 | 0.510 |
Why?
| | Cricetulus | 7 | 2019 | 108 | 0.510 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 44 | 0.500 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1343 | 0.500 |
Why?
| | Mutagenesis | 2 | 2019 | 182 | 0.470 |
Why?
| | Stents | 2 | 2016 | 522 | 0.450 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 161 | 0.440 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 48 | 0.440 |
Why?
| | Oligodendroglia | 4 | 2025 | 178 | 0.430 |
Why?
| | Optic Atrophy | 2 | 2011 | 8 | 0.430 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 5733 | 0.420 |
Why?
| | Temporal Arteries | 4 | 2015 | 44 | 0.420 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 154 | 0.420 |
Why?
| | Male | 49 | 2025 | 67386 | 0.410 |
Why?
| | Intracranial Hypotension | 2 | 2025 | 56 | 0.410 |
Why?
| | Peptide Fragments | 4 | 2023 | 690 | 0.390 |
Why?
| | Antigens, Viral | 3 | 2015 | 178 | 0.390 |
Why?
| | Visual Acuity | 6 | 2021 | 361 | 0.380 |
Why?
| | Flow Cytometry | 9 | 2023 | 1189 | 0.380 |
Why?
| | Axons | 2 | 2022 | 195 | 0.370 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 47 | 0.370 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 110 | 0.370 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 4 | 0.370 |
Why?
| | Autoantigens | 5 | 2025 | 421 | 0.370 |
Why?
| | Hemodynamics | 1 | 2016 | 1062 | 0.360 |
Why?
| | Recurrence | 7 | 2023 | 1059 | 0.360 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 35 | 0.350 |
Why?
| | Cricetinae | 6 | 2019 | 294 | 0.350 |
Why?
| | Gene Targeting | 1 | 2011 | 82 | 0.350 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 154 | 0.350 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 96 | 0.340 |
Why?
| | Nerve Degeneration | 1 | 2010 | 46 | 0.340 |
Why?
| | Eye Diseases | 2 | 2020 | 86 | 0.340 |
Why?
| | Stilbenes | 1 | 2010 | 36 | 0.340 |
Why?
| | Young Adult | 17 | 2025 | 13218 | 0.340 |
Why?
| | Nerve Regeneration | 1 | 2010 | 58 | 0.330 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 37 | 0.330 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 592 | 0.320 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 20 | 0.310 |
Why?
| | Immune System Phenomena | 1 | 2009 | 2 | 0.310 |
Why?
| | Meningioma | 2 | 2023 | 93 | 0.310 |
Why?
| | Virus Diseases | 1 | 2011 | 212 | 0.310 |
Why?
| | Rats | 12 | 2021 | 5544 | 0.300 |
Why?
| | Adolescent | 18 | 2024 | 21471 | 0.300 |
Why?
| | Cell Survival | 2 | 2019 | 1124 | 0.300 |
Why?
| | Aged | 22 | 2025 | 23803 | 0.290 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2139 | 0.290 |
Why?
| | Nervous System Diseases | 2 | 2020 | 270 | 0.290 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 113 | 0.280 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 126 | 0.280 |
Why?
| | Ophthalmology | 2 | 2007 | 90 | 0.280 |
Why?
| | Neurology | 2 | 2007 | 110 | 0.280 |
Why?
| | Protein Binding | 7 | 2025 | 2223 | 0.270 |
Why?
| | Cerebral Cortex | 3 | 2023 | 433 | 0.270 |
Why?
| | Antibodies | 3 | 2017 | 406 | 0.270 |
Why?
| | Peptide Library | 5 | 2025 | 95 | 0.270 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 138 | 0.260 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 20 | 0.260 |
Why?
| | Immunization, Passive | 3 | 2020 | 91 | 0.260 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 47 | 0.260 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1975 | 0.260 |
Why?
| | Transcriptome | 4 | 2020 | 966 | 0.260 |
Why?
| | Mutation | 6 | 2019 | 3975 | 0.250 |
Why?
| | Corpus Callosum | 1 | 2006 | 70 | 0.250 |
Why?
| | Antibody Formation | 1 | 2007 | 294 | 0.250 |
Why?
| | Gyrus Cinguli | 2 | 2024 | 88 | 0.250 |
Why?
| | Proteomics | 2 | 2012 | 1106 | 0.250 |
Why?
| | Herpes Zoster | 3 | 2015 | 313 | 0.240 |
Why?
| | Prospective Studies | 10 | 2024 | 7512 | 0.240 |
Why?
| | Atrophy | 2 | 2023 | 188 | 0.240 |
Why?
| | B-Lymphocyte Subsets | 2 | 2024 | 76 | 0.230 |
Why?
| | Syndecan-1 | 4 | 2011 | 36 | 0.230 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 27 | 0.230 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2025 | 55 | 0.230 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2025 | 243 | 0.230 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 176 | 0.230 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2025 | 58 | 0.230 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 23 | 0.230 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 11 | 0.220 |
Why?
| | Acute Disease | 3 | 2018 | 993 | 0.220 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 44 | 0.220 |
Why?
| | Touch Perception | 1 | 2024 | 18 | 0.220 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 50 | 0.220 |
Why?
| | Nystagmus, Pathologic | 1 | 2024 | 13 | 0.220 |
Why?
| | Retrospective Studies | 11 | 2024 | 15536 | 0.210 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2024 | 12 | 0.210 |
Why?
| | Cerebellar Ataxia | 1 | 2024 | 13 | 0.210 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 28 | 0.210 |
Why?
| | Consciousness | 1 | 2024 | 27 | 0.210 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1470 | 0.210 |
Why?
| | Blindness, Cortical | 1 | 2003 | 5 | 0.210 |
Why?
| | Risk Assessment | 4 | 2021 | 3446 | 0.210 |
Why?
| | Proteoglycans | 1 | 2004 | 107 | 0.210 |
Why?
| | Proteolipids | 1 | 2023 | 30 | 0.210 |
Why?
| | Paraplegia | 1 | 2024 | 60 | 0.210 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 182 | 0.210 |
Why?
| | Epitope Mapping | 4 | 2017 | 61 | 0.200 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 839 | 0.200 |
Why?
| | Seroconversion | 1 | 2023 | 45 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 143 | 0.200 |
Why?
| | Neuroprotection | 1 | 2023 | 42 | 0.200 |
Why?
| | Immune System | 1 | 2004 | 178 | 0.200 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 239 | 0.200 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 141 | 0.190 |
Why?
| | Vision Disorders | 2 | 2021 | 143 | 0.190 |
Why?
| | Cells, Cultured | 7 | 2016 | 4136 | 0.190 |
Why?
| | Hippocampus | 2 | 2021 | 897 | 0.190 |
Why?
| | Incidence | 3 | 2025 | 2793 | 0.190 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2900 | 0.190 |
Why?
| | Zika Virus | 1 | 2023 | 128 | 0.190 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2156 | 0.190 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1747 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 561 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 496 | 0.180 |
Why?
| | Antibody Affinity | 2 | 2019 | 60 | 0.180 |
Why?
| | Protein Isoforms | 4 | 2017 | 392 | 0.180 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 189 | 0.180 |
Why?
| | Zika Virus Infection | 1 | 2023 | 165 | 0.170 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 28 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1626 | 0.170 |
Why?
| | Internationality | 2 | 2019 | 158 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 34 | 0.170 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1134 | 0.170 |
Why?
| | Schizophrenia | 2 | 2022 | 443 | 0.170 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 47 | 0.170 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 43 | 0.170 |
Why?
| | Animals, Newborn | 3 | 2018 | 832 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2020 | 2456 | 0.160 |
Why?
| | Azathioprine | 1 | 2020 | 49 | 0.160 |
Why?
| | Visual Pathways | 3 | 2023 | 56 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 746 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 782 | 0.160 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 33 | 0.160 |
Why?
| | Amygdala | 1 | 2021 | 188 | 0.160 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.160 |
Why?
| | Viral Vaccines | 1 | 2020 | 107 | 0.160 |
Why?
| | Cell Separation | 2 | 2015 | 314 | 0.160 |
Why?
| | Prevalence | 2 | 2024 | 2732 | 0.160 |
Why?
| | Steroids | 1 | 2020 | 157 | 0.150 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 15 | 0.150 |
Why?
| | Child | 13 | 2024 | 21760 | 0.150 |
Why?
| | Treatment Outcome | 11 | 2024 | 10664 | 0.150 |
Why?
| | Models, Molecular | 3 | 2025 | 1591 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 60 | 0.150 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 10 | 0.150 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 7 | 0.150 |
Why?
| | Cell Lineage | 1 | 2020 | 352 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 96 | 0.150 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 448 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2020 | 161 | 0.150 |
Why?
| | Neurogenesis | 3 | 2016 | 149 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.140 |
Why?
| | Peptides | 2 | 2019 | 975 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 389 | 0.140 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 79 | 0.140 |
Why?
| | Point Mutation | 1 | 2019 | 237 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 62 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 268 | 0.140 |
Why?
| | Spatial Analysis | 1 | 2017 | 20 | 0.130 |
Why?
| | Skull Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Mice, Knockout | 9 | 2017 | 2999 | 0.130 |
Why?
| | Sphenoid Bone | 1 | 2017 | 17 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 5688 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 79 | 0.130 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 40 | 0.130 |
Why?
| | Antibodies, Viral | 4 | 2023 | 646 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 539 | 0.130 |
Why?
| | Orbital Diseases | 1 | 2017 | 32 | 0.130 |
Why?
| | Albumins | 1 | 2017 | 116 | 0.130 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 107 | 0.130 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 372 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 907 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5048 | 0.130 |
Why?
| | Microvessels | 1 | 2017 | 88 | 0.130 |
Why?
| | Fibrinogen | 1 | 2017 | 170 | 0.130 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 604 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 781 | 0.120 |
Why?
| | Interferon-beta | 2 | 2025 | 92 | 0.120 |
Why?
| | HEK293 Cells | 4 | 2022 | 727 | 0.120 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 321 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 488 | 0.120 |
Why?
| | Ethics, Research | 1 | 2015 | 34 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 338 | 0.120 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 5 | 0.120 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 8 | 0.120 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 408 | 0.120 |
Why?
| | Aged, 80 and over | 8 | 2021 | 7559 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 367 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 365 | 0.120 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.120 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 241 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.110 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 1 | 0.110 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 76 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3661 | 0.110 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 859 | 0.110 |
Why?
| | Plasma Exchange | 1 | 2014 | 15 | 0.110 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 94 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 95 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2019 | 705 | 0.110 |
Why?
| | Alanine | 1 | 2015 | 151 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 971 | 0.110 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 264 | 0.110 |
Why?
| | Glycine | 1 | 2015 | 175 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2015 | 0.110 |
Why?
| | Erythropoietin | 1 | 2014 | 94 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2013 | 17 | 0.100 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2463 | 0.100 |
Why?
| | Fetal Death | 1 | 2013 | 57 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Antibody Specificity | 2 | 2011 | 187 | 0.100 |
Why?
| | Neurons | 5 | 2024 | 1586 | 0.100 |
Why?
| | Autism Spectrum Disorder | 2 | 2016 | 400 | 0.100 |
Why?
| | Biomedical Research | 1 | 2019 | 700 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2111 | 0.100 |
Why?
| | Computer Simulation | 1 | 2017 | 982 | 0.100 |
Why?
| | Syndrome | 2 | 2019 | 371 | 0.100 |
Why?
| | Proteome | 2 | 2015 | 470 | 0.100 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 79 | 0.100 |
Why?
| | Phenotype | 3 | 2020 | 3148 | 0.100 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 164 | 0.090 |
Why?
| | Exanthema | 1 | 2013 | 78 | 0.090 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 38 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 660 | 0.090 |
Why?
| | Antigens, CD20 | 2 | 2023 | 29 | 0.090 |
Why?
| | Area Postrema | 1 | 2011 | 1 | 0.090 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 6 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 144 | 0.090 |
Why?
| | Cranial Sinuses | 1 | 2011 | 14 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 110 | 0.090 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 16 | 0.090 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 30 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2017 | 784 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1630 | 0.090 |
Why?
| | Fundus Oculi | 1 | 2011 | 66 | 0.090 |
Why?
| | Cerebral Angiography | 2 | 2011 | 109 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2015 | 737 | 0.090 |
Why?
| | Quality of Life | 1 | 2023 | 2899 | 0.090 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 79 | 0.090 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 154 | 0.090 |
Why?
| | Brain Mapping | 2 | 2024 | 506 | 0.080 |
Why?
| | United States | 2 | 2025 | 14945 | 0.080 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 8 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 242 | 0.080 |
Why?
| | Risk Factors | 4 | 2016 | 10363 | 0.080 |
Why?
| | Cell Line | 3 | 2011 | 2855 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 3931 | 0.080 |
Why?
| | Spinal Puncture | 1 | 2009 | 17 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 195 | 0.080 |
Why?
| | Pregnancy | 5 | 2023 | 6736 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1700 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 1114 | 0.080 |
Why?
| | Databases, Factual | 1 | 2015 | 1367 | 0.080 |
Why?
| | Genes | 1 | 2009 | 228 | 0.080 |
Why?
| | Brain Injuries | 1 | 2014 | 493 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 6786 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 41 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2013 | 526 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 634 | 0.070 |
Why?
| | Clone Cells | 3 | 2017 | 263 | 0.070 |
Why?
| | Optic Disk | 1 | 2008 | 45 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3556 | 0.070 |
Why?
| | Transfection | 3 | 2018 | 934 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 30 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 522 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 522 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 16 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 266 | 0.070 |
Why?
| | Molecular Biology | 2 | 2009 | 58 | 0.070 |
Why?
| | Health | 1 | 2007 | 83 | 0.070 |
Why?
| | Visual Fields | 1 | 2007 | 90 | 0.070 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 11 | 0.070 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 5 | 0.070 |
Why?
| | Measles virus | 1 | 2006 | 16 | 0.070 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 26 | 0.070 |
Why?
| | Bevacizumab | 1 | 2007 | 135 | 0.060 |
Why?
| | Puerperal Disorders | 1 | 2007 | 31 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 97 | 0.060 |
Why?
| | Vitreous Body | 1 | 2007 | 107 | 0.060 |
Why?
| | Binding, Competitive | 2 | 2019 | 194 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 39 | 0.060 |
Why?
| | Models, Immunological | 1 | 2006 | 100 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 227 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5530 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 105 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 353 | 0.060 |
Why?
| | Spatio-Temporal Analysis | 2 | 2016 | 34 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1151 | 0.060 |
Why?
| | Myelography | 1 | 2025 | 37 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 797 | 0.060 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2025 | 60 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1441 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3393 | 0.060 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 545 | 0.060 |
Why?
| | Child, Preschool | 4 | 2021 | 10952 | 0.060 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 265 | 0.050 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 51 | 0.050 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 20 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2654 | 0.050 |
Why?
| | Touch | 1 | 2024 | 36 | 0.050 |
Why?
| | Risk | 1 | 2007 | 901 | 0.050 |
Why?
| | Fistula | 1 | 2024 | 47 | 0.050 |
Why?
| | Somatosensory Cortex | 1 | 2024 | 36 | 0.050 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 42 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2025 | 190 | 0.050 |
Why?
| | Granzymes | 1 | 2024 | 49 | 0.050 |
Why?
| | Ataxia | 1 | 2024 | 70 | 0.050 |
Why?
| | Patient Selection | 1 | 2008 | 685 | 0.050 |
Why?
| | Geniculate Bodies | 1 | 2023 | 19 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2024 | 62 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2371 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2851 | 0.050 |
Why?
| | Receptors, IgG | 1 | 2023 | 77 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 222 | 0.050 |
Why?
| | Headache | 1 | 2024 | 146 | 0.050 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 11 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 13 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 95 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1083 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 23 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 67 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2006 | 965 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 153 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 38 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2708 | 0.050 |
Why?
| | Antigens, Surface | 1 | 2022 | 152 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2015 | 309 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 101 | 0.050 |
Why?
| | Eye | 1 | 2002 | 107 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 382 | 0.050 |
Why?
| | Primates | 1 | 2022 | 139 | 0.050 |
Why?
| | Binding Sites | 2 | 2017 | 1310 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 277 | 0.040 |
Why?
| | Glycoproteins | 1 | 2023 | 356 | 0.040 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 35 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 291 | 0.040 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 8 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3258 | 0.040 |
Why?
| | Base Sequence | 1 | 2004 | 2168 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 182 | 0.040 |
Why?
| | Aging | 2 | 2024 | 1849 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1923 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 352 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 675 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 117 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 491 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 305 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 13 | 0.040 |
Why?
| | Serum | 1 | 2019 | 59 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 734 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 173 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1780 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2015 | 873 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2021 | 293 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 165 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 868 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 47 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1452 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1278 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 290 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2009 | 354 | 0.030 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 19 | 0.030 |
Why?
| | Clonal Deletion | 1 | 2017 | 16 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 648 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3266 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 27 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 21 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 167 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 76 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1301 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 222 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 151 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 135 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 100 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 5 | 0.030 |
Why?
| | Neocortex | 1 | 2016 | 38 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 193 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1774 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2016 | 235 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 531 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 108 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 850 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 495 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 99 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 370 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 365 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 307 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 583 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 421 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 49 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 465 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 43 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 514 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2016 | 165 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 363 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 249 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 20 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | SOXC Transcription Factors | 1 | 2013 | 5 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 40 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 21 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 62 | 0.030 |
Why?
| | Neurodevelopmental Disorders | 1 | 2016 | 182 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 542 | 0.020 |
Why?
| | Narcolepsy | 1 | 2013 | 21 | 0.020 |
Why?
| | Multigene Family | 1 | 2013 | 199 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 27 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 4 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 451 | 0.020 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 247 | 0.020 |
Why?
| | Interneurons | 1 | 2013 | 122 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 716 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 189 | 0.020 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 112 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 87 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 41 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 37 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 9 | 0.020 |
Why?
| | Vaccination | 1 | 2020 | 1428 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 197 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2809 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 206 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 566 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 303 | 0.020 |
Why?
| | Genome | 1 | 2013 | 300 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 318 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 156 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 661 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 133 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 234 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1730 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1019 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 145 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 214 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 126 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 41 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 37 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2182 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 757 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1706 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 421 | 0.020 |
Why?
| | Water | 1 | 2012 | 465 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 168 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 157 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 254 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 346 | 0.020 |
Why?
| | Virion | 1 | 2009 | 113 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 239 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 815 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 462 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 367 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 567 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1256 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1083 | 0.020 |
Why?
| | Glioma | 1 | 2010 | 399 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 749 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 2070 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1382 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 7 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 10 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 12 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1180 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 824 | 0.010 |
Why?
| | Infant | 1 | 2017 | 9392 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 735 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2574 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 647 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1460 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1543 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 5047 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 5812 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|